Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 123Carcinoma, Hepatocellular 72Breast Neoplasms 48Neoplasms 47Small Cell Lung Carcinoma 45Lung Neoplasms 41Triple Negative Breast Neoplasms 40Colorectal Neoplasms 38Melanoma 35Urinary Bladder Neoplasms 33Neoplasm Metastasis 31Carcinoma, Transitional Cell 31Carcinoma, Renal Cell 28Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 13Prostatic Neoplasms 12Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Endometrial Neoplasms 9Mesothelioma, Malignant 8Kidney Neoplasms 8

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1fludarabine 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solid Cancer × atezolizumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated
7 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡